Natasha Martin

Title(s)Professor, Medicine
SchoolVc-health Sciences-schools
Address9500 Gilman Drive #
La Jolla CA 92093
vCardDownload vCard

    Collapse Biography 
    Collapse Education and Training
    Oxford University, Oxford, UKDPhil/PhD2009Mathematical biology
    Stanford University, Palo Alto, CABS2003Mathematics, biology

    Collapse Overview 
    Collapse Overview
    Dr. Natasha Martin is an infectious disease economic modeler who develops dynamic transmission models to evaluate the impact and cost-effectiveness of public health interventions. She is currently a Professor in the Division of Infectious Diseases and Global Public Health at the University of California San Diego and holds an honorary senior lecturer position at the University of Bristol. She directs the NIDA-funded T32 program in Substance Use, HIV, and related syndemics along with MPI Steffanie Strathdee, which trains pre and postdoctoral fellows. She is the MPI on the UC GloCal Health Fellowship, which provides one year of funding to conduct global health research abroad ( Finally, she is co-director of the Biostatistics and Modeling Core of the University of California San Diego Center for AIDS Research (UCSD CFAR). She has worked for over 2 decades developing mathematical models of disease progression and transmission in both communicable and non-communicable diseases. For the past twelve years, her primary research has focused on modeling hepatitis C virus (HCV) and HIV transmission and prevention among high-risk groups such as people who inject drugs (PWID), men who have sex with men, and female sex workers. She is a leading researcher on modeling the impact of HCV treatment as prevention. Additionally, she has experience developing dynamic cost-effectiveness evaluations of case-finding and prevention interventions, and has the only published cost-effectiveness models of HCV case-finding interventions and treatment including both individual and population benefits. She is the principal investigator (PI) of a NIAID/NIDA-funded R01 optimizing HIV and HCV prevention portfolios among people who inject drugs in 108 countries. Her modeling work informed the WHO guidelines “When to start ART in people living with HIV (2013)”, and her work on the impact and cost-effectiveness of HCV treatment among people who inject drugs informed the WHO guidelines on “Hepatitis C testing, care, and treatment (2013)”. More recently, her modeling work on HCV elimination was used to inform the WHO “Global Health Sector Strategy on Viral Hepatitis 2016-2021”.

    Collapse Research 
    Collapse Research Activities and Funding
    Miami Dade County ASsessment of Phylogenetics to Improve Resource Equity: MD ASPIRE
    NIMH R01MH132151Jul 1, 2022 - Jun 30, 2027
    Role: MPI
    Description: To date, the use of HIV molecular surveillance has not been linked to a reduction in HIV incidence. The proposed project will perform secondary analyses of coded and de-identified public health HIV surveillance data from the Los Angeles County (LAC) Health Department. The study team will engage key stakeholder populations and use regional estimates of HIV transmission and HIV program data to project the impact of alternative strategies for the optimal allocation of resources to LAC HIV prevention programs relevant to EHE targets.
    Simulation Modeling to Support the Public Health Response to the Opioid Crisis in North America
    NIH R13DA052198Jun 1, 2021 - May 31, 2024
    Role: Co-Principal Investigator
    Ethno-epidemiology of HCV, HIV and Overdose associated with Drug Markets and Drug Tourism
    NIH/NIDA R01DA049644Apr 1, 2020 - Jan 31, 2025
    Role: Co-Investigator
    Optimizing HIV prevention portfolios targeting people who inject drugs using dynamic economic modeling
    NIH R01AI147490Aug 7, 2019 - Jul 31, 2023
    Role: Principal Investigator
    Integrating HCV services into HIV programs for PWID in India
    NIH R01AI145555Jul 8, 2019 - Jun 30, 2024
    Role: Co-Investigator
    University of California, San Diego, Center for AIDS Research
    NIH 5 P30 AI036214Apr 1, 2018 - Mar 31, 2023
    Role: Co-Director, Biostatistics and Modeling Core
    Modeling Structural HIV Determinants in Substance Users and related populations
    NIH R01DA037773Apr 1, 2015 - Dec 31, 2018
    Role: Principal Investigator
    The Impact of HCV Treatment in HIV/HCV coinfected and HCV monoinfected Incarcerated Persons on HCV Elimination
    NIH R01DA013806Sep 20, 2000 - Aug 31, 2025
    Role: Co-Investigator
    Modeling opioid overdose and prevention in Australia
    Australian NHMRC Dec 31, 2023
    Role: Co-I
    Evaluating the Population Impact of Hepatitis C Direct Acting Antiviral Treatment as Prevention for People Who Inject Drugs (EPIToPe).
    UK National Institute for Health Research Feb 1, 2023
    Role: Co-investigator
    HCV elimination among men who have sex with men in Germany
    Gilead Jun 1, 2022
    Role: Co-investigator
    Impact of direct acting antivirals uptake in controlling hepatitis C epidemic and modeling interventions for hepatitis C elimination among HIV-infected persons in San Diego
    Gilead Jan 1, 2021
    Role: Co-PI
    Modeling HCV elimination among HIV-infected men who have sex with men and people who inject drugs
    Gilead Dec 31, 2020
    Role: Principal Investigator
    Testing and comparing study designs for evaluating HCV treatment as prevention (TasP) impact in a real world setting
    Merck Dec 1, 2020
    Role: Principal Investigator
    Cost-effectiveness of HCV testing and treatment in pregnant women
    Gilead Apr 30, 2020
    Role: Principal Investigator
    Surveillance and Treatment of Prisoners with hepatitis C (STOP-C)
    Australian NHMRC Dec 31, 2019
    Role: Co-Investigator
    Description: To test HCV treatment as prevention among prisoners in New South Wales, Australia. Overseeing modeling to inform trial design, implementation and evaluation.

    Collapse ORNG Applications 
    Collapse Featured Publications

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help. to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    Altmetrics Details PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Evaluating the power of the causal impact method in observational studies of HCV treatment as prevention. Stat Commun Infect Dis. 2021 Jan 01; 13(1):20200005. Samartsidis P, Martin NN, De Gruttola V, De Vocht F, Hutchinson S, Lok JJ, Puenpatom A, Wang R, Hickman M, De Angelis D. PMID: 35880998; PMCID: PMC9204771.
      View in: PubMed   Mentions:
    2. Scaling Up Hepatitis C Prevention and Treatment Interventions for Achieving Elimination in the United States: A Rural and Urban Comparison. Am J Epidemiol. 2019 08 01; 188(8):1539-1551. Fraser H, Vellozzi C, Hoerger TJ, Evans JL, Kral AH, Havens J, Young AM, Stone J, Handanagic S, Hariri S, Barbosa C, Hickman M, Leib A, Martin NK, Nerlander L, Raymond HF, Page K, Zibbell J, Ward JW, Vickerman P. PMID: 31150044; PMCID: PMC7415256.
      View in: PubMed   Mentions: 21     Fields:    Translation:Humans
    3. Cost-effectiveness and budgetary impact of HCV treatment with direct-acting antivirals in India including the risk of reinfection. PLoS One. 2019; 14(6):e0217964. Chaillon A, Mehta SR, Hoenigl M, Solomon SS, Vickerman P, Hickman M, Skaathun B, Martin NK. PMID: 31170246; PMCID: PMC6553784.
      View in: PubMed   Mentions: 9     Fields:    Translation:Humans
    4. The contribution of injection drug use to hepatitis C virus transmission globally, regionally, and at country level: a modelling study. Lancet Gastroenterol Hepatol. 2019 06; 4(6):435-444. Trickey A, Fraser H, Lim AG, Peacock A, Colledge S, Walker JG, Leung J, Grebely J, Larney S, Martin NK, Hickman M, Degenhardt L, May MT, Vickerman P. PMID: 30981685; PMCID: PMC6698583.
      View in: PubMed   Mentions: 63     Fields:    Translation:HumansPHPublic Health
    5. Primary Incidence of Hepatitis C Virus Infection Among HIV-Infected Men Who Have Sex With Men in San Diego, 2000-2015. Open Forum Infect Dis. 2019 Apr; 6(4):ofz160. Chaillon A, Sun X, Cachay ER, Looney D, Wyles D, Garfein RS, Martin TCS, Martin TCS, Jain S, Mehta SR, Smith DM, Little SJ, Martin NK. PMID: 31041355; PMCID: PMC6483132.
      View in: PubMed   Mentions: 14  
    6. A matched comparison study of hepatitis C treatment outcomes in the prison and community setting, and an analysis of the impact of prison release or transfer during therapy. J Viral Hepat. 2016 12; 23(12):1009-1016. Aspinall EJ, Mitchell W, Schofield J, Cairns A, Lamond S, Bramley P, Peters SE, Valerio H, Tomnay J, Goldberg DJ, Mills PR, Barclay ST, Fraser A, Dillon JF, Martin NK, Hickman M, Hutchinson SJ. PMID: 27509844; PMCID: PMC5558600.
      View in: PubMed   Mentions: 27     Fields:    Translation:Humans
    7. New treatments for hepatitis C virus (HCV): scope for preventing liver disease and HCV transmission in England. J Viral Hepat. 2016 08; 23(8):631-43. Harris RJ, Martin NK, Rand E, Mandal S, Mutimer D, Vickerman P, Ramsay ME, De Angelis D, Hickman M, Harris HE. PMID: 27025238; PMCID: PMC4982023.
      View in: PubMed   Mentions: 19     Fields:    Translation:HumansPHPublic Health
    8. HCV treatment rates and sustained viral response among people who inject drugs in seven UK sites: real world results and modelling of treatment impact. J Viral Hepat. 2015 Apr; 22(4):399-408. Martin NK, Foster GR, Vilar J, Ryder S, Cramp ME, Gordon F, Dillon JF, Craine N, Busse H, Clements A, Hutchinson SJ, Ustianowski A, Ramsay M, Goldberg DJ, Irving W, Hope V, De Angelis D, Lyons M, Vickerman P, Hickman M. PMID: 25288193; PMCID: PMC4409099.
      View in: PubMed   Mentions: 46     Fields:    Translation:HumansCells
    9. Assessing the cost-effectiveness of finding cases of hepatitis C infection in UK migrant populations and the value of further research. J Viral Hepat. 2014; 21(9):616-23. Miners AH, Martin NK, Ghosh A, Hickman M, Vickerman P. PMID: 24215210.
      View in: PubMed   Mentions: 8     Fields:    Translation:Humans
    10. A general reaction-diffusion model of acidity in cancer invasion. J Math Biol. 2014 Apr; 68(5):1199-224. McGillen JB, Gaffney EA, Martin NK, Maini PK. PMID: 23536240.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansCells
    11. C-reactive protein is a useful predictor of metronidazole treatment failure in mild-to-moderate Clostridium difficile infection. Eur J Gastroenterol Hepatol. 2013 Jan; 25(1):33-6. Farne HA, Martin NK, Main J, Orchard T, Tyrrell-Price J. PMID: 23026925.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansCells
    12. Could low dead-space syringes really reduce HIV transmission to low levels? Int J Drug Policy. 2013 Jan; 24(1):8-14. Vickerman P, Martin NK, Hickman M. PMID: 23206493.
      View in: PubMed   Mentions: 13     Fields:    Translation:HumansAnimalsPHPublic Health
    13. Pancreatic insufficiency in patients with HIV infection: role of didanosine questioned. HIV Med. 2013 Mar; 14(3):161-6. Martin TC, Scourfield A, Rockwood N, Martin NK, Martin NK, Patel N, Nelson M, Gazzard BG. PMID: 22994793.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    14. Predicting the safety and efficacy of buffer therapy to raise tumour pHe: an integrative modelling study. Br J Cancer. 2012 Mar 27; 106(7):1280-7. Martin NK, Robey IF, Gaffney EA, Gillies RJ, Gatenby RA, Maini PK. PMID: 22382688; PMCID: PMC3314784.
      View in: PubMed   Mentions: 20     Fields:    Translation:HumansAnimals
    15. Bicarbonate and dichloroacetate: evaluating pH altering therapies in a mouse model for metastatic breast cancer. BMC Cancer. 2011 Jun 10; 11:235. Robey IF, Martin NK. PMID: 21663677; PMCID: PMC3125283.
      View in: PubMed   Mentions: 29     Fields:    Translation:HumansAnimalsCells
    16. A mathematical model of tumour and blood pHe regulation: The HCO3-/CO2 buffering system. Math Biosci. 2011 Mar; 230(1):1-11. Martin NK, Gaffney EA, Gatenby RA, Gillies RJ, Robey IF, Maini PK. PMID: 21167185; PMCID: PMC3045481.
      View in: PubMed   Mentions: 16     Fields:    Translation:HumansAnimalsCells
    17. Tumour-stromal interactions in acid-mediated invasion: a mathematical model. J Theor Biol. 2010 Dec 07; 267(3):461-70. Martin NK, Gaffney EA, Gatenby RA, Maini PK. PMID: 20816684; PMCID: PMC3005191.
      View in: PubMed   Mentions: 21     Fields:    Translation:HumansAnimalsCells
    18. Leaky vessels as a potential source of stromal acidification in tumours. J Theor Biol. 2010 Dec 07; 267(3):454-60. Martin NK, Gaffney EA, Gatenby RA, Maini PK. PMID: 20699102; PMCID: PMC2963718.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansAnimals
    Natasha's Networks
    Concepts (113)
    Derived automatically from this person's publications.
    Co-Authors (13)
    People in Profiles who have published with this person.
    Similar People (60)
    People who share similar concepts with this person.
    Same Department
    Search Department